Repare Therapeutics Inc (RPTX) has released an update.
Repare Therapeutics Inc. has been notified by Roche that their collaborative licensing agreement for the development and commercialization of certain ATR inhibitors, including camonsertib, will be terminated without cause, effective May 7, 2024. Despite this, Repare will regain all rights to these products and is set to receive a $40 million milestone payment from Roche. The company confirmed this update through a press release, marking the end of their material relationship with Roche post-termination date.
For further insights into RPTX stock, check out TipRanks’ Stock Analysis page.
